Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/193790

Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Pancreatic β-cells are an essential source of insulin and their destruction because of autoimmunity causes type I diabetes. We conducted a chemical screen to identify compounds that would induce the differentiation of insulin-producing β-cells in vivo. To do this screen, we brought together the use of transgenic zebrafish as a model of β-cell differentiation, a unique multiwell plate that allows easy visualization of lateral views of swimming larval fish and a library of clinical drugs. We identified six hits that can induce precocious differentiation of secondary islets in larval zebrafish. Three of these six hits were known drugs with a considerable background of published data on mechanism of action. Using pharmacological approaches, we have identified and characterized two unique pathways in β-cell differentiation in the zebrafish, including down-regulation of GTP production and retinoic acid biosynthesis.

Citació

Citació

ROVIRA, Meritxell, HUANG, Wei, YUSUFF, Shamila, SHIM, Joong sup, FERRANTE, Anthony a., LIU, Jun o., PARSONS, Michael j.. Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. _Proceedings of the National Academy of Sciences of the United States of America - PNAS_. 2011. Vol. 108, núm. 48. [consulta: 24 de gener de 2026]. ISSN: 0027-8424. [Disponible a: https://hdl.handle.net/2445/193790]

Exportar metadades

JSON - METS

Compartir registre